Peptide-assisted delivery of steric-blocking antisense oligomers

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 2, 2003, Pages 123-132

  Moulton, Hong M ^a   Moulton, Jon D ^b  

^a AVI BIOPHARMA INC   (United States)

^b Gene Tools LLC   (United States)

Author keywords

2 O methoxyethylphosphorothioate; 2 O methylphosphorothioate; Ant; Cell permeable peptides; Morpholino; PMO; PNA; SV 40; Tat

Indexed keywords

2' O ALKYL PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; ARGININE; DNA; OLIGOMER; PEPTIDE; PEPTIDE NUCLEIC ACID; PHOSPHORODIAMIDATE MORPHOLINO; PHOSPHOROTHIOIC ACID; TRYPSIN; UNCLASSIFIED DRUG;

ARTIFACT; BACTERIUM; CELL CULTURE; CELL MEMBRANE; CELL NUCLEUS; CELL SURFACE; CYTOSOL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG UPTAKE; ENDOCYTOSIS; ENDOSOME; EUKARYOTIC CELL; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HISTOLOGY; HUMAN; MOUSE; NONHUMAN; PROTEIN BINDING; REVIEW; SIGNAL NOISE RATIO;

CARRIER PROTEINS; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FORECASTING; GENE PRODUCTS, TAT; MOLECULAR PROBES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; PEPTIDES; UP-REGULATION;

BACTERIA (MICROORGANISMS); EUKARYOTA; FORMICIDAE;

EID: 0038814141     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Summerton J: Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim Biophys Acta (1999) 1489(1):141-158.
2. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA (1989) 86(10):3474-3478.
3. Kos R, Reedy MV, Johnson RL, Erickson CA: The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos. Development (2001) 128(8):1467-1479.
4. Nasevicius A, Ekker SC: Effective targeted gene 'knockdown' in zebrafish. Nat Genet (2000) 26(2):216-220.
5. Ghosh C, Iversen PL: Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Dev (2000) 10(4):263-274.
6. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D, Kole R: Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol (2002) 20(12):1228-1233.
7. Morcos PA: Achieving efficient delivery of morpholino oligos in cultured cells. Genesis (2001) 30(3):94-102.
8. Summerton J, Weller D: Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev (1997) 7:187-195.
9. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD: Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev (1996) 6(4):267-272.
10. Ekker SC, Larson JD: Morphant technology in model developmental systems. Genesis (2001) 30(3):89-93.
11. Arora V, Kroeker AD, Reddy MT: Cytochrome P450 3A2 antisense morpholino oligomer AVI-4472: A 14-day toxicity study in male rats. Toxicol Sci (2002) 66:107.
12. Arora V, Hannah TL, Iversen PL, Brand RM: Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm Res (2002) 19(10):1465-1470.
13. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL: Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci (2002) 91(4):1009-1018
14. Nielsen PE, Egholm M, Berg RH, Buchardt O: Sequence selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science (1991) 254(5037):1497-1500.
15. Moulton HM, Hase MC, Smith CM, Iversen PL: HIV Tat peptide enhances cellular delivery of antisense Morpholino oligomers. Antisense Nucleic Acid Drug Dev (2003) 13(1):31-43.
16. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chemomordik LV, Lebleu B: Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem (2003) 278(1):585-590.
17. Stein CA: Keeping the biotechnology of antisense in context. Nat Biotechnol (1999) 17(3):209.
18. Yan YL, Miller CT, Nissen RM, Singer A, Liu D, Kim A, Draper B, Willoughby J, Morcos PA, Amsterdam A, Chung BC et al: A zebrafish sox9 gene required for cartilage morphogenesis. Development (2002) 129(21):5065-5079.
19. Kole R, Sazani P: Antisense effects in the cell nucleus: Modification of splicing. Curr Opin Mol Ther (2001) 3(3):229-234.
20. Sazani P, Kang SH, Maier M, Wei C, Dillman J, Summerton J, Manoharan M, Kole R: Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res (2001) 29(19):3965-3974.
21. Kang SH, Cho MJ, Kole R: Upregulation of luciferase gene expression with antisense oligonucleotides: Implications and applications in functional assay development. Biochemistry (1998) 37(18):6235-6239.
22. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL: Conjugates of antisense oligonucleotides with the Tat and Antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res (2002) 19(6):744-754.
23. McKeon J, Cho MJ, Khaledi MG: Quantitation of intracellular concentration of a delivered morpholino oligomer by capillary electrophoresis-laser-induced fluorescence: Correlation with upregulation of luciferase gene expression. Anal Biochem (2001) 293(1):1-7.
24. McKeon J, Khaledi MG: Quantitative nuclear and cytoplasmic localization of antisense oligonucleotides by capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis (2001) 22(17):3765-3770.
25. Sun L, Fuselier JA, Murphy WA, Coy DH: Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxity to human neuroblastoma IMR32 cells expressing somatostatin receptors. Peptides (2002) 23(9):1557-1565.
26. Koppelhus U, Awasthi SK, Zachar V, Holst HU, Ebbesen P, Nielsen PE: Cell-dependent differential cellular uptake of PNA, peptides and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev (2002) 12(2):51-63.
27. Braun K, Peschke P, Pipkorn R, Lampel S, Wachmuth M, Waldeck W, Friedrich E, Debus J: A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J Mol Biol (2002) 318(2):237-243.
28. Brandén LJ, Christensson B, Smith CI: In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides. Gene Ther (2001) 8(1):84-87.
29. Penco S, Scarfi S, Giovine M, Damonte G, Millo E, Villaggio B, Passalacqua M, Pozzolini M, Garre C, Benatti U: Identification of an import signal for, and the nuclear localization of, human lactoferrin. Biotechnol Appl Biochem, (2001) 34(Pt 3):151-159.
30. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB: The design, synthesis and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci USA (2000) 97(24):13003-13008.
31. Morris MC, Depollier J, Mery J, Heitz F, Divita G: A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol (2001) 19(12):1173-1176.
32. Kaushik N, Basu A, Palumbo P, Myers RL, Pandey VN: Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J Virol (2002) 76(8):3881-3891.
33. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF: Synthetic protein transduction domains: Enhanced transduction potential in vitro and in vivo. Cancer Res (2001) 61(2):474-477.
34. Lewis MR, Jia F, Gallazzi F, Wang Y, Zhang J, Shenoy N, Lever SZ, Hannink M: Radiometal-labeled peptide-PNA conjugates for targeting Bcl-2 expression: Preparation, characterization, and in vitro mRNA binding. Bioconjug Chem (2002) 13(6):1176-1180.
35. Eriksson M, Neilsen PE, Good L: Cell permeabilization and uptake of antisense peptide-peptide nucleic acid (PNA) into Escherichia coli. J Biol Chem (2002) 277(9):7144-7147.
36. Vives E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 272(25):16010-16017.
37. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A: Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem (1996) 271(30):18188-18193.
38. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y: Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem (2001) 276(8):5836-5840.
39. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y: Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem (2002) 277(4):2437-2443.
40. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL, Wender PA: Arginine-rich molecular transporters for drug delivery: Role of backbone spacing in cellular uptake. J Med Chem (2002) 45(17):3612-3618.
41. Fisher AA, Ye D, Sergueev DS, Fisher MH, Shaw BR, Juliano RL: Evaluating the specificity of antisense oligonucleotide conjugates. A DNA army analysis. J Biol Chem (2002) 227(25):22980-22984.
42. Karras JG, Maier MA, Lu T, Watt A, Manoharan M: Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-α chain. Biochemistry (2001) 40(26):7853-7859.
43. Rapozzi V, Burm BE, Cogoi S, van der Marel GA, van Boom JH, Quadrifoglio F, Xodo LE: Anti-proliferative effect in chronic myeloid leukemia cells by antisense peptide nucleic acids. Nucleic Acids Res (2002) 30(17):3712-3721.
44. Good L, Awasthi SK, Dryselius R, Larsson O, Nielsen PE: Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol (2001) 19(4):360-364.
45. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, Kahl U, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Hokfelt T et al: Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol (1998) 16(9):857-861.
46. Lee HJ, Pardridge WM: Pharmacokinetics and delivery of Tat and Tat-protein conjugates to tissues in vivo. Bioconjug Chem (2001) 12(6):995-999.
47. Rozema DB, Ekena K, Lewis DL, Loomis AG, Wolff JA: Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules. Bioconjug Chem (2003) 14(1):51-57.